Gilead's top late-stage drug selonsertib ... advanced fibrosis due to NASH, which will be announced later this year. NASH is a chronic and progressive liver disease characterised by fat ...

NASH is less deadly, particularly in its early stages, but affects a large and ... have the potential to treat devastating and major liver diseases. Now, Promethera is poised to validate the ...

[40] If FFA are agents of destruction in the pathogenesis of liver disease, abundant and overlapping ... Staging for fibrosis Stage 1: zone 3 perivenular, peri-sinusoidal, or pericellular fibrosis ...